Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Status unconfirmed
Conditions studied: Neuroendocrine Tumor
In brief
This pilot research trial studies molecular analysis in tissue samples from patients with advanced or metastatic neuroendocrine tumors. Studying samples of tissue from patients with neuroendocrine tumors in the lab may help doctors identify mutations to classify disease and plan the best treatment.
Key facts
- Study ID
- NCT02092714
- Run by
- Fox Chase Cancer Center
- People needed
- 90
- Starts
- 2013-10-16
- Expected to finish
- 2020-11-16
- Last updated by the study team
- 2019-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Pathologically or cytologically confirmed neuroendocrine tumor which is metastatic, locally advanced or otherwise incurable (of any grade or primary site, excluding small cell lung cancers, large cell lung cancers, and Merkel cell carcinomas)
- Evaluable disease by radiographic imaging
- Adequate available tumor tissue (formalin-fixed paraffin-embedded [FFPE] tissue or cytologic material) for sequencing (containing > 50% tumor cellularity by histopathology) or consent to tumoral biopsy for fresh tissue; adequacy will be determined by our pathology department, under supervision of Dr. Gustafson
- Ability to understand and willingness to sign a written informed consent and Health Information Portability and Accountability Act (HIPAA) consent document
- Life expectancy of >= 6 months
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2
You may not qualify if…
- Localized neuroendocrine tumor for which the patient is eligible for a potentially curative surgical intervention
- Primary diagnosis of pulmonary small cell carcinoma, pulmonary large cell carcinoma or Merkel cell carcinoma
- Inability to provide informed consent
- Inadequate tissue available for genetic testing
- Any secondary active malignancy, excluding non-melanoma skin cancers; if the patient's prognosis will be primarily determined by their neuroendocrine tumor, the secondary malignancy is to be discounted
Where it is running
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.